Orgenesis(US:ORGS)2021-03-09 21:35Financial Data and Key Metrics Changes - Revenue nearly doubled in 2020 to $7.7 million, up from $3.9 million in 2019, representing a 96% increase attributed to growth in technology transfer and validation of cell therapies [31][39] - Cash and cash equivalents at year-end were approximately $44.9 million, with no long-term debt, indicating a solid financial position [42] Business Line Data and Key Metrics Changes - The company sold its Masthercell subsidiary for $315 million, generating approximately $127 million in net proceeds, which will accelerate the point-of-care strategy [7][10] - The revenue run rate for the CDMO business increased from $3 million to approximately $30 million at the end of 2019, reflecting a compound annual growth rate of 59% [9] Market Data and Key Metrics Changes - Partnerships established with leading hospitals and research centers in 14 countries, facilitating a global distribution platform for therapies [19][24] - The company has developed or licensed more than 30 therapies, with ongoing discussions to expand its pipeline [16][26] Company Strategy and Development Direction - The strategic focus is on developing a decentralized point-of-care platform to lower costs and enhance accessibility of cell and gene therapies [12][13] - The company aims to integrate advanced automation technologies into its point-of-care systems to streamline production and distribution [15][17] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in achieving more than doubling revenue in 2021 based on existing contracts [31][42] - The company anticipates that the point-of-care model will significantly reduce therapy costs, making treatments more accessible to patients [12][35] Other Important Information - The company has received government support for many projects, which is expected to continue, aiding in reducing healthcare costs [36][100] - The company has a robust patent portfolio, with 28 U.S. patents and numerous pending applications, providing a competitive advantage [29] Q&A Session Summary Question: Deployment of OMPULs and targeted development programs - Management indicated that OMPULs have not yet been publicly disclosed in terms of hospital deployment but are adaptable to various therapies, particularly in immuno-oncology [45][46] Question: Contribution of Kyslecel to revenue - Kyslecel contributed minor revenue in Q4, with expectations for significant revenue growth once adapted for automated mobile systems [46][50] Question: Highlighting specific programs for clinical trials in 2021 - Focus will be on immuno-oncology products, with plans to advance several therapies into clinical trials [51][52] Question: Economics for hospitals and revenue potential for Orgenesis - Management outlined a model where one OMPUL could generate product for 70-100 patients annually, aiming to reduce therapy costs significantly [58][60] Question: Impediments to growth in the U.S. - Validation and regulatory processes are seen as the main challenges, but management is optimistic about overcoming these hurdles [62][63] Question: Nature of the $40 million revenue projection - Revenue will come from initial tech transfer and validation payments, with expectations for future royalties as therapies progress [67][72] Question: Hiring focus and areas for expansion - Recent hires have focused on processing, quality systems, and clinical development, with plans to continue expanding in these areas [75][78] Question: Response from hospitals to the point-of-care model - Hospitals are increasingly interested in the point-of-care model, which addresses the need for regulated therapies that can be produced efficiently [104]